Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEpe Special Opp Regulatory News (ESO)

Share Price Information for Epe Special Opp (ESO)

Share Price is delayed by 15 minutes
Get Live Data
237.00    -1.00 (-0.42%)
Bid:
232.00
Ask:
242.00
Spread: 10.00 (4.31%)
Market Cap: £58.41m
ESO Live PriceLast checked at - London Stock Exchange

Intraday Epe Special Opp Share Chart

Portfolio Update

29 Mar 2018 07:00

RNS Number : 3283J
EPE Special Opportunities PLC
29 March 2018
 

EPE Special Opportunities plc

29 March 2018

 

This announcement contains inside information

 

EPE Special Opportunities plcPortfolio Update

EPE Special Opportunities plc ("ESO plc", or the "Company") announces that Pharmacy2U Limited ("P2U"), a company in which it has a minority investment via ESO Investments 1 LP ("ESO 1 LP"), has raised a further £40 million of new growth capital to support the rapid expansion of its online NHS repeat prescription service.

P2U is England's leading online NHS pharmacy and is the fastest growing pharmacy group in the country, with 25,000 new patient registrations in the last month alone and year-on-year growth in patient numbers of 178%.

As well as offering consumers increased choice and convenience, P2U's online prescription management service is highly beneficial for the healthcare economy, saving GPs an estimated six hours and 40 minutes a week on paperwork. It is estimated that managing repeat prescriptions online could save the NHS over £300 million per year on prescription costs.

The growth capital raise was led by G Square Capital, a European private equity firm focussed on the healthcare sector. In conjunction with the new investment, G Square Capital also acquired a majority of the share capital of P2U from existing shareholders and as a result is now the majority shareholder.

The new investment will allow P2U to invest further in technology infrastructure to support customer demand and remain at the forefront of innovation in digital pharmacy services. P2U's state-of-the-art, award winning dispensing facility in Leeds is already the largest and most technologically advanced in the United Kingdom, with the ability to dispense one million prescription items per month.

ESO 1 LP has realised 50% of its existing investment in P2U in the transaction, implying a 2.0x Money Multiple realised return. The transaction was completed at a premium to the holding value of P2U. The remaining 50% of ESO 1 LP's investment has been retained to benefit from the growth potential in P2U offered by the £40 million investment. This retained investment offers further upside in terms of Money Multiple returns to ESO 1 LP

The person responsible for releasing this information on behalf of the Company is Hilary Jones of R&H Fund Services (Jersey) Limited.

 

Enquiries:

 

EPIC Private Equity LLP

+44 (0) 207 269 8865

Alex Leslie

R&H Fund Services (Jersey) Limited

+44 (0) 1534 825 323

Hilary Jones

Cardew Group Limited

+44 (0) 207 930 0777

Richard Spiegelberg

Numis Securities Limited

+44 (0) 207 260 1000

Nominated Advisor:

Stuart Skinner / Hugh Jonathan

Corporate Broker:

Charles Farquhar

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
PFUDBGDXXBDBGII
Date   Source Headline
4th Jun 20267:00 amRNSTransaction in Own Shares
3rd Jun 20267:00 amRNSTransaction in Own Shares
1st Jun 20265:00 pmRNSHolding(s) in Company
1st Jun 20264:25 pmRNSTransaction in Own Shares
1st Jun 20267:00 amRNSAnnouncement of Share Buy Backs
29th May 20261:30 pmRNSDirector/PDMR Shareholding
27th May 20264:00 pmRNSPartial Sell Down of Investment in Luceco plc
8th May 20267:00 amRNSNet Asset Value(s)
28th Apr 20265:05 pmRNSHolding(s) in Company
28th Apr 20265:00 pmRNSDirector/PDMR Shareholding
28th Apr 20267:15 amRNSDirector/PDMR Shareholding
23rd Apr 20267:15 amRNSHolding(s) in Company
16th Apr 20262:50 pmRNSHolding(s) in Company
16th Apr 20262:45 pmRNSDirector/PDMR Shareholding
15th Apr 20269:12 amRNSNet Asset Value(s)
14th Apr 20267:00 amRNSDirector/PDMR Shareholding
9th Apr 20267:00 amRNSDirector/PDMR Shareholding
25th Mar 20267:00 amRNSAnnual Financial Report
20th Feb 20266:22 pmRNSUpdate on Share Buy Backs
18th Feb 20261:00 pmRNSTransaction in Own Shares
17th Feb 20265:10 pmRNSHolding(s) in Company
17th Feb 20265:00 pmRNSHolding(s) in Company
17th Feb 20261:35 pmRNSTransaction in Own Shares
13th Feb 20267:00 amRNSAnnouncement of Share Buy Backs
9th Feb 20267:00 amRNSTrading Statement
4th Feb 20267:00 amRNSInterest Payment on Unsecured Loan Notes
15th Jan 20267:00 amRNSNet Asset Value(s)
22nd Dec 20257:00 amRNSUpdate on Share Buy Backs
22nd Dec 20257:00 amRNSUpdate on Share Buy Backs
11th Dec 20257:00 amRNSNet Asset Value(s)
4th Dec 20257:00 amRNSTransaction in Own Shares
2nd Dec 20257:03 amRNSTransaction in Own Shares
1st Dec 20257:00 amRNSTransaction in Own Shares
27th Nov 20257:08 amRNSTransaction in Own Shares
25th Nov 20257:00 amRNSTransaction in Own Shares
20th Nov 20257:00 amRNSTransaction in Own Shares
14th Nov 20257:00 amRNSNet Asset Value(s)
13th Nov 20257:00 amRNSTransaction in Own Shares
11th Nov 20257:00 amRNSTransaction in Own Shares
7th Nov 20257:00 amRNSTransaction in Own Shares
6th Nov 20257:00 amRNSTransaction in Own Shares
5th Nov 20257:00 amRNSTransaction in Own Shares
4th Nov 20257:00 amRNSTransaction in Own Shares
24th Oct 20257:00 amRNSTransaction in Own Shares
20th Oct 20257:00 amRNSTransaction in Own Shares
17th Oct 20257:00 amRNSDirector/PDMR Shareholding
17th Oct 20257:00 amRNSHolding(s) in Company
17th Oct 20257:00 amRNSTransaction in Own Shares
16th Oct 202510:15 amRNSAnnouncement of Ordinary and ZDP Share Buybacks
23rd Sep 20257:00 amRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.